Inventiva Sa (IVA NASDAQ) stock market data APIs
$6.1754
-0.04(-0.6%)
as of March 17, 2026
Try our APIs with
free plan!
Inventiva Sa Financial Data Overview
Price chart is built with
Anychart
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Prev. Close
6.1754
Open
6.1331
High
6.2798
Low
6.1102
52 wk Range
2.7-7.9825
Market Cap
557 M
Shares Outstanding
146 M
Revenue
16 970 K
EPS
-0.3
Beta
0.775
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Inventiva Sa (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inventiva Sa data using free add-ons & libraries
Get Inventiva Sa Fundamental Data
Inventiva Sa Fundamental data includes:
- Net Revenue: 16 970 K
- EBITDA: -95 789 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-21
- EPS/Forecast: -0.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inventiva Sa News
New
Inventiva reports preliminary 2025¹ fiscal year financial results
Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gros...
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹
Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 202...
Take the Zacks Approach to Beat the Markets: Hershey's, Fastenal, Kennametal in Focus
Last Friday, the three most widely followed benchmark indexes closed a mixed week. The S&P 500 and the Nasdaq Composite receded 0.1% and 1.9%, respectively, while the Dow Jones Industrial Average adva...
Biotech Inventiva's 50% surge shows investor optimism over liver disease drug
By Danilo Masoni MILAN, Jan 28 (Reuters) - A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for betting on the loss-making French biotech, whic...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
